Small-molecule PET Tracers for Imaging Proteinopathies

Seminars in Nuclear Medicine

Volumn 47, Issue 5, 2017, Pages 553-575

  Mathis, Chester A ^a   Lopresti, Brian J ^a   Ikonomovic, Milos D ^a   Klunk, William E ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; AMYLOID PROTEIN; PITTSBURGH COMPOUND B; RADIOLIGAND; TAU PROTEIN; TRACER;

ALPHA SYNUCLEINOPATHY; ALZHEIMER DISEASE; CRYSTALLOGRAPHY; DEGENERATIVE DISEASE; DISEASE CLASSIFICATION; DISORDERS OF AMINO ACID AND PROTEIN METABOLISM; HUMAN; NEUROIMAGING; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; REVIEW; TAUOPATHY; DIAGNOSTIC IMAGING; MOLECULAR LIBRARY;

ALPHA-SYNUCLEIN; ALZHEIMER DISEASE; HUMANS; NEURODEGENERATIVE DISEASES; POSITRON-EMISSION TOMOGRAPHY; SMALL MOLECULE LIBRARIES; TAU PROTEINS;

EID: 85023597040     PISSN: 00012998     EISSN: 15584623     Source Type: Journal    
DOI: 10.1053/j.semnuclmed.2017.06.003     Document Type: Review

References (254)

1. Ezkurdia, I., Juan, D., Rodriguez, J.M., et al. Multiple evidence strands suggest that there may be as few as 19,000 human protein-coding genes. Hum Mol Genet 23 (2014), 5866–5878.
2. Kumar, V., Sami, N., Kashav, T., et al. Protein aggregation and neurodegenerative diseases: From theory to therapy. Eur J Med Chem 124 (2016), 1105–1120.
3. Stroo, E., Koopman, M., Nollen, E.A., et al. Cellular regulation of amyloid formation in aging and disease. Front Neurosci, 11, 2017, 64.
4. Wong, Y.C., Krainc, D., alpha-Synuclein toxicity in neurodegeneration: Mechanism and therapeutic strategies. Nat Med 23 (2017), 1–13.
5. Bourdenx, M., Koulakiotis, N.S., Sanoudou, D., et al. Protein aggregation and neurodegeneration in prototypical neurodegenerative diseases: Examples of amyloidopathies, tauopathies and synucleinopathies. Prog Neurobiol 155 (2017), 171–193.
6. Saa, P., Harris, D.A., Cervenakova, L., Mechanisms of prion-induced neurodegeneration. Expert Rev Mol Med, 18, 2016, e5.
7. Prusiner, S.B., Biology and genetics of prions causing neurodegeneration. Annu Rev Genet 47 (2013), 601–623.
8. Will, R.G., Ironside, J.W., Sporadic and infectious human prion diseases. Cold Spring Harb Perspect Med, 7, 2017.
9. Wechalekar, A.D., Gillmore, J.D., Hawkins, P.N., Systemic amyloidosis. Lancet 387 (2016), 2641–2654.
10. Sipe, J.D., Benson, M.D., Buxbaum, J.N., et al. Amyloid fibril proteins and amyloidosis: Chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines. Amyloid 23 (2016), 209–213.
11. Walker, L.C., LeVine, H. 3rd, Corruption and spread of pathogenic proteins in neurodegenerative diseases. J Biol Chem 287 (2012), 33109–33115.
12. Patterson, B.W., Elbert, D.L., Mawuenyega, K.G., et al. Age and amyloid effects on human central nervous system amyloid-beta kinetics. Ann Neurol 78 (2015), 439–453.
13. Prokop, S., Miller, K.R., Heppner, F.L., Microglia actions in Alzheimer's disease. Acta Neuropathol 126 (2013), 461–477.
14. Krebs, M.R., Bromley, E.H., Donald, A.M., The binding of thioflavin-T to amyloid fibrils: Localisation and implications. J Struct Biol 149 (2005), 30–37.
15. Pulawski, W., Ghoshdastider, U., Andrisano, V., et al. Ubiquitous amyloids. Appl Biochem Biotechnol 166 (2012), 1626–1643.
16. Schleiden, M.J., Leipzig, F.A.B.V., Grundzüge der wissenschaftlichen Botanik: nebst einer methodologischen Einleitung als Anleitung zum Studium der Pflanze. Vol. T. 1-2. 1842, Verlag von Wilhelm Engelmann, Leipzig.
17. Cohen, A.S., General introduction and a brief history of the amyloid fibril. Marrink, J., Van Rijswijk, M.H., (eds.) Amyloidosis, 1986, Nijhoff, Dordrecht, 3–19.
18. Rohn, T.T., Corpora amylacea in neurodegenerative diseases: Cause or effect?. Int J Neurol Neurother, 2, 2015.
19. Friedreich, N., Kekulé, A., Zur Amyloidfrage. Archiv für pathologische Anatomie und Physiologie und für klinische Medicin 16 (1859), 50–65.
20. Makin, O.S., Serpell, L.C., Structures for amyloid fibrils. FEBS J 272 (2005), 5950–5961.
21. Alzheimer, A., Stelzmann, R.A., Schnitzlein, H.N., et al. An English translation of Alzheimer's 1907 paper, “Uber eine eigenartige Erkankung der Hirnrinde.”. Clin Anat 8 (1995), 429–431.
22. Tycko, R., Alzheimer's disease: Structure of aggregates revealed. Nature 537 (2016), 492–493.
23. Daebel, V., Chinnathambi, S., Biernat, J., et al. beta-Sheet core of tau paired helical filaments revealed by solid-state NMR. J Am Chem Soc 134 (2012), 13982–13989.
24. Peterson, D.W., Zhou, H., Dahlquist, F.W., et al. A soluble oligomer of tau associated with fiber formation analyzed by NMR. Biochemistry 47 (2008), 7393–7404.
25. Eisenberg, D.S., Sawaya, M.R., Implications for Alzheimer's disease of an atomic resolution structure of amyloid-beta(1-42) fibrils. Proc Natl Acad Sci USA 113 (2016), 9398–9400.
26. Rodriguez, J.A., Ivanova, M.I., Sawaya, M.R., et al. Structure of the toxic core of alpha-synuclein from invisible crystals. Nature 525 (2015), 486–490.
27. Feligioni, M., Marcelli, S., Iannuzzi, F., et al. The involvement of post-translational modifications in Alzheimer's disease. Curr Alzheimer Res, 2017, 10.2174/1567205014666170505095109.
28. Guo, T., Noble, W., Hanger, D.P., Roles of tau protein in health and disease. Acta Neuropathol 133 (2017), 665–704.
29. Vicente Miranda, H., Szego, E.M., Oliveira, L.M., et al. Glycation potentiates alpha-synuclein-associated neurodegeneration in synucleinopathies. Brain, 2017, 10.1093/brain/awx056.
30. Scherpelz, K.P., Lu, J.X., Tycko, R., et al. Preparation of amyloid fibrils seeded from brain and meninges. Methods Mol Biol 1345 (2016), 299–312.
31. Peelaerts, W., Bousset, L., Van der Perren, A., et al. alpha-Synuclein strains cause distinct synucleinopathies after local and systemic administration. Nature 522 (2015), 340–344.
32. Duyckaerts, C., Neurodegenerative lesions: Seeding and spreading. Rev Neurol (Paris) 169 (2013), 825–833.
33. Jucker, M., Walker, L.C., Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders. Ann Neurol 70 (2011), 532–540.
34. Xiao, Y., Ma, B., McElheny, D., et al. Abeta(1-42) fibril structure illuminates self-recognition and replication of amyloid in Alzheimer's disease. Nat Struct Mol Biol 22 (2015), 499–505.
35. Tuttle, M.D., Comellas, G., Nieuwkoop, A.J., et al. Solid-state NMR structure of a pathogenic fibril of full-length human alpha-synuclein. Nat Struct Mol Biol 23 (2016), 409–415.
36. Laruelle, M., Slifstein, M., Huang, Y., Relationships between radiotracer properties and image quality in molecular imaging of the brain with positron emission tomography. Mol Imaging Biol 5 (2003), 363–375.
37. Pike, V.W., Considerations in the development of reversibly binding PET radioligands for brain imaging. Curr Med Chem 23 (2016), 1818–1869.
38. Bennhold, H., Specific staining of amyloid by Congo red. Muenchen Med Wochenschr 69 (1922), 1537–1538.
39. Divry, P., Etude histochimique des plaques seniles. J Belge Neurol Psychiat 27 (1927), 643–657.
40. Vassar, P.S., Culling, C.F., Fluorescent stains, with special reference to amyloid and connective tissues. Arch Pathol 68 (1959), 487–498.
41. Elghetany, M.T., Saleem, A., Methods for staining amyloid in tissues: A review. Stain Technol 63 (1988), 201–212.
42. Shoghi-Jadid, K., Small, G.W., Agdeppa, E.D., et al. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am J Geriatr Psychiatry 10 (2002), 24–35.
43. Shin, J., Kepe, V., Barrio, J.R., et al. The merits of FDDNP-PET imaging in Alzheimer's disease. J Alzheimers Dis 26:suppl 3 (2011), 135–145.
44. Kepe, V., Ghetti, B., Farlow, M.R., et al. PET of brain prion protein amyloid in Gerstmann-Straussler-Scheinker disease. Brain Pathol 20 (2010), 419–430.
45. Barrio, J.R., Small, G.W., Wong, K.P., et al. In vivo characterization of chronic traumatic encephalopathy using [F-18]FDDNP PET brain imaging. Proc Natl Acad Sci USA 112 (2015), E2039–E2047.
46. Kepe, V., Bordelon, Y., Boxer, A., et al. PET imaging of neuropathology in tauopathies: Progressive supranuclear palsy. J Alzheimers Dis 36 (2013), 145–153.
47. Styren, S.D., Hamilton, R.L., Styren, G.C., et al. X-34, a fluorescent derivative of Congo red: A novel histochemical stain for Alzheimer's disease pathology. J Histochem Cytochem 48 (2000), 1223–1232.
48. Link, C.D., Johnson, C.J., Fonte, V., et al. Visualization of fibrillar amyloid deposits in living, transgenic Caenorhabditis elegans animals using the sensitive amyloid dye, X-34. Neurobiol Aging 22 (2001), 217–226.
49. Ikonomovic, M.D., Abrahamson, E.E., Isanski, B.A., et al. X-34 labeling of abnormal protein aggregates during the progression of Alzheimer's disease. Methods Enzymol 412 (2006), 123–144.
50. Klunk, W.E., Bacskai, B.J., Mathis, C.A., et al. Imaging Abeta plaques in living transgenic mice with multiphoton microscopy and methoxy-X04, a systemically administered Congo red derivative. J Neuropathol Exp Neurol 61 (2002), 797–805.
51. Sadowski, M., Pankiewicz, J., Scholtzova, H., et al. Targeting prion amyloid deposits in vivo. J Neuropathol Exp Neurol 63 (2004), 775–784.
52. Brendza, R.P., Bacskai, B.J., Cirrito, J.R., et al. Anti-Abeta antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice. J Clin Invest 115 (2005), 428–433.
53. Koenigsknecht-Talboo, J., Meyer-Luehmann, M., Parsadanian, M., et al. Rapid microglial response around amyloid pathology after systemic anti-Abeta antibody administration in PDAPP mice. J Neurosci 28 (2008), 14156–14164.
54. Burgold, S., Bittner, T., Dorostkar, M.M., et al. In vivo multiphoton imaging reveals gradual growth of newborn amyloid plaques over weeks. Acta Neuropathol 121 (2011), 327–335.
55. Bertoncini, C.W., Celej, M.S., Small molecule fluorescent probes for the detection of amyloid self-assembly in vitro and in vivo. Curr Protein Pept Sci 12 (2011), 205–220.
56. Mathis, C.A., Wang, Y., Holt, D.P., et al. Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem 46 (2003), 2740–2754.
57. Klunk, W.E., Engler, H., Nordberg, A., et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 55 (2004), 306–319.
58. Klunk, W.E., Mathis, C.A., Whatever happened to Pittsburgh Compound-A?. Alzheimer Dis Assoc Disord 22 (2008), 198–203.
59. Mathis, C.A., Wang, Y., Klunk, W.E., Imaging beta-amyloid plaques and neurofibrillary tangles in the aging human brain. Curr Pharm Des 10 (2004), 1469–1492.
60. Mathis, C.A., Mason, N.S., Lopresti, B.J., et al. Development of positron emission tomography beta-amyloid plaque imaging agents. Semin Nucl Med 42 (2012), 423–432.
61. Mathis, C.A., Bacskai, B.J., Kajdasz, S.T., et al. A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain. Bioorg Med Chem Lett 12 (2002), 295–298.
62. Klunk, W.E., Wang, Y., Huang, G.F., et al. Uncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain. Life Sci 69 (2001), 1471–1484.
63. Klunk, W.E., Wang, Y., Huang, G.F., et al. The binding of 2-(4'-methylaminophenyl)benzothiazole to postmortem brain homogenates is dominated by the amyloid component. J Neurosci 23 (2003), 2086–2092.
64. Ikonomovic, M.D., Klunk, W.E., Abrahamson, E.E., et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 131:Pt 6 (2008), 1630–1645.
65. Lockhart, A., Lamb, J.R., Osredkar, T., et al. PIB is a non-specific imaging marker of amyloid-beta (Abeta) peptide-related cerebral amyloidosis. Brain 130:Pt 10 (2007), 2607–2615.
66. Fodero-Tavoletti, M.T., Smith, D.P., McLean, C.A., et al. In vitro characterization of Pittsburgh compound-B binding to Lewy bodies. J Neurosci 27 (2007), 10365–10371.
67. Ye, L., Velasco, A., Fraser, G., et al. In vitro high affinity alpha-synuclein binding sites for the amyloid imaging agent PIB are not matched by binding to Lewy bodies in postmortem human brain. J Neurochem 105 (2008), 1428–1437.
68. Klunk, W.E., Lopresti, B.J., Ikonomovic, M.D., et al. Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain. J Neurosci 25 (2005), 10598–10606.
69. Price, J.C., Klunk, W.E., Lopresti, B.J., et al. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab 25 (2005), 1528–1547.
70. Mathis, C.A., Holt, D., Wang, Y.M., et al. Species-dependent formation and identification of the brain metabolites of the amyloid imaging agent [C-11]PiB. Neurobiol Aging 25:suppl 2 (2004), S277–S278.
71. Cole, G.B., Keum, G., Liu, J., et al. Specific estrogen sulfotransferase (SULT1E1) substrates and molecular imaging probe candidates. Proc Natl Acad Sci USA 107 (2010), 6222–6227.
72. McNamee, R.L., Yee, S.H., Price, J.C., et al. Consideration of optimal time window for Pittsburgh compound B PET summed uptake measurements. J Nucl Med 50 (2009), 348–355.
73. Lopresti, B.J., Klunk, W.E., Mathis, C.A., et al. Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: A comparative analysis. J Nucl Med 46 (2005), 1959–1972.
74. Tolboom, N., Yaqub, M., Boellaard, R., et al. Test-retest variability of quantitative [11C]PIB studies in Alzheimer's disease. Eur J Nucl Med Mol Imaging 36 (2009), 1629–1638.
75. van Berckel, B.N., Ossenkoppele, R., Tolboom, N., et al. Longitudinal amyloid imaging using 11C-PiB: Methodologic considerations. J Nucl Med 54 (2013), 1570–1576.
76. Yaqub, M., Tolboom, N., Boellaard, R., et al. Simplified parametric methods for [11C]PIB studies. Neuroimage 42 (2008), 76–86.
77. Aizenstein, H.J., Nebes, R.D., Saxton, J.A., et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol 65 (2008), 1509–1517.
78. Cohen, A.D., Mowrey, W., Weissfeld, L.A., et al. Classification of amyloid-positivity in controls: Comparison of visual read and quantitative approaches. Neuroimage 71 (2013), 207–215.
79. Knopman, D.S., Jack, C.R. Jr, Lundt, E.S., et al. Evolution of neurodegeneration-imaging biomarkers from clinically normal to dementia in the Alzheimer disease spectrum. Neurobiol Aging 46 (2016), 32–42.
80. Lao, P.J., Betthauser, T.J., Hillmer, A.T., et al. The effects of normal aging on amyloid-beta deposition in nondemented adults with Down syndrome as imaged by carbon 11-labeled Pittsburgh compound B. Alzheimers Dement 12 (2016), 380–390.
81. Lim, H.K., Nebes, R., Snitz, B., et al. Regional amyloid burden and intrinsic connectivity networks in cognitively normal elderly subjects. Brain 137:Pt 12 (2014), 3327–3338.
82. Mathis, C.A., Kuller, L.H., Klunk, W.E., et al. In vivo assessment of amyloid-beta deposition in nondemented very elderly subjects. Ann Neurol 73 (2013), 751–761.
83. Mintun, M.A., Larossa, G.N., Sheline, Y.I., et al. 11C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease. Neurology 67 (2006), 446–452.
84. Pike, K.E., Savage, G., Villemagne, V.L., et al. Beta-amyloid imaging and memory in non-demented individuals: Evidence for preclinical Alzheimer's disease. Brain 130:Pt 11 (2007), 2837–2844.
85. Rowe, C.C., Ng, S., Ackermann, U., et al. Imaging beta-amyloid burden in aging and dementia. Neurology 68 (2007), 1718–1725.
86. Villemagne, V.L., Pike, K.E., Chetelat, G., et al. Longitudinal assessment of Abeta and cognition in aging and Alzheimer disease. Ann Neurol 69 (2011), 181–192.
87. Jansen, W.J., Ossenkoppele, R., Knol, D.L., et al. Prevalence of cerebral amyloid pathology in persons without dementia: A meta-analysis. JAMA 313 (2015), 1924–1938.
88. Chetelat, G., La Joie, R., Villain, N., et al. Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer's disease. Neuroimage Clin 2 (2013), 356–365.
89. Sperling, R.A., Rentz, D.M., Johnson, K.A., et al. The A4 study: Stopping AD before symptoms begin?. Sci Transl Med, 6, 2014, 228fs13.
90. Mills, S.M., Mallmann, J., Santacruz, A.M., et al. Preclinical trials in autosomal dominant AD: Implementation of the DIAN-TU trial. Rev Neurol (Paris) 169 (2013), 737–743.
91. Hsu, D., Marshall, G.A., Primary and secondary prevention trials in Alzheimer disease: Looking back, moving forward. Curr Alzheimer Res 14 (2017), 426–440.
92. Reiman, E.M., Langbaum, J.B., Fleisher, A.S., et al. Alzheimer's Prevention Initiative: A plan to accelerate the evaluation of presymptomatic treatments. J Alzheimers Dis 26:suppl 3 (2011), 321–329.
93. Clark, C.M., Schneider, J.A., Bedell, B.J., et al. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA 305 (2011), 275–283.
94. Wolk, D.A. I., Grachev, D., Buckley, C., et al. Association between in vivo fluorine 18-labeled flutemetamol amyloid positron emission tomography imaging and in vivo cerebral cortical histopathology. Arch Neurol 68 (2011), 1398–1403.
95. Rinne, J.O., Wong, D.F., Wolk, D.A., et al. [(18)F]Flutemetamol PET imaging and cortical biopsy histopathology for fibrillar amyloid beta detection in living subjects with normal pressure hydrocephalus: Pooled analysis of four studies. Acta Neuropathol 124 (2012), 833–845.
96. Sabri, O., Sabbagh, M.N., Seibyl, J., et al. Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: Phase 3 study. Alzheimers Dement 11 (2015), 964–974.
97. Rinne, J.O., Brooks, D.J., Rossor, M.N., et al. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: A phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 9 (2010), 363–372.
98. Sevigny, J., Chiao, P., Bussiere, T., et al. The antibody aducanumab reduces Abeta plaques in Alzheimer's disease. Nature 537 (2016), 50–56.
99. Siemers, E.R., Sundell, K.L., Carlson, C., et al. Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients. Alzheimers Dement 12 (2016), 110–120.
100. Panza, F., Solfrizzi, V., Imbimbo, B.P., et al. Efficacy and safety studies of gantenerumab in patients with Alzheimer's disease. Expert Rev Neurother 14 (2014), 973–986.
101. Johnson, K.A., Minoshima, S., Bohnen, N.I., et al. Appropriate use criteria for amyloid PET: A report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. J Nucl Med 54 (2013), 476–490.
102. Johnson, K.A., Minoshima, S., Bohnen, N.I., et al. Update on appropriate use criteria for amyloid PET imaging: Dementia experts, mild cognitive impairment, and education. J Nucl Med 54 (2013), 1011–1013.
103. Arbizu, J., Garcia-Ribas, G., Carrio, I., et al. Recommendations for the use of PET imaging biomarkers in the diagnosis of neurodegenerative conditions associated with dementia: SEMNIM and SEN consensus. Rev Esp Med Nucl Imagen Mol 34 (2015), 303–313.
104. Grundman, M., Johnson, K.A., Lu, M., et al. Effect of amyloid imaging on the diagnosis and management of patients with cognitive decline: Impact of appropriate use criteria. Dement Geriatr Cogn Disord 41 (2016), 80–92.
105. Laforce, R., Rosa-Neto, P., Soucy, J.P., et al. Canadian consensus guidelines on use of amyloid imaging in Canada: Update and future directions from the specialized task force on amyloid imaging in Canada. Can J Neurol Sci 43 (2016), 503–512.
106. Minoshima, S., Drzezga, A.E., Barthel, H., et al. SNMMI procedure standard/EANM practice guideline for amyloid PET imaging of the brain 1.0. J Nucl Med 57 (2016), 1316–1322.
107. Bielschowsky, M., Brodmann, K., Zur feineren histologie und histopathologie der grosshirnrinde. J Psychol Neurol 5 (1905), 173–199.
108. Kidd, M., Paired helical filaments in electron microscopy of Alzheimer's disease. Nature 197 (1963), 192–193.
109. Wischik, C.M., Novak, M., Thogersen, H.C., et al. Isolation of a fragment of tau derived from the core of the paired helical filament of Alzheimer disease. Proc Natl Acad Sci USA 85 (1988), 4506–4510.
110. Goedert, M., Wischik, C.M., Crowther, R.A., et al. Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: Identification as the microtubule-associated protein tau. Proc Natl Acad Sci USA 85 (1988), 4051–4055.
111. Terry, R.D., The fine structure of neurofibrillary tangles in Alzheimer's disease. J Neuropathol Exp Neurol 22 (1963), 629–642.
112. Maccioni, R.B., Cambiazo, V., Role of microtubule-associated proteins in the control of microtubule assembly. Physiol Rev 75 (1995), 835–864.
113. Mandelkow, E., Mandelkow, E.M., Microtubules and microtubule-associated proteins. Curr Opin Cell Biol 7 (1995), 72–81.
114. Arriagada, P.V., Growdon, J.H., Hedley-Whyte, E.T., et al. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology 42:Pt 1 (1992), 631–639 3.
115. Bancher, C., Jellinger, K., Lassmann, H., et al. Correlations between mental state and quantitative neuropathology in the Vienna Longitudinal Study on Dementia. Eur Arch Psychiatry Clin Neurosci 246 (1996), 137–146.
116. Berg, L., McKeel, D.W. Jr, Miller, J.P., et al. Clinicopathologic studies in cognitively healthy aging and alzheimer disease: Relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Arch Neurol 55 (1998), 326–335.
117. Bierer, L.M., Hof, P.R., Purohit, D.P., et al. Neocortical neurofibrillary tangles correlate with dementia severity in alzheimer's disease. Arch Neurol 52 (1995), 81–88.
118. Giannakopoulos, P., Herrmann, F.R., Bussière, T., et al. Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer's disease. Neurology 60 (2003), 1495–1500.
119. Nagy, Z., Esiri, M.M., Jobst, K.A., et al. Relative roles of plaques and tangles in the dementia of Alzheimer's disease: Correlations using three sets of neuropathological criteria. Dementia 6 (1995), 21–31.
120. Nelson, P.T., Alafuzoff, I., Bigio, E.H., et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: A review of the literature. J Neuropathol Exp Neurol 71 (2012), 362–381.
121. Xia, C., Makaretz, S.J., Caso, C., et al. Association of in vivo [18F]AV-1451 tau pet imaging results with cortical atrophy and symptoms in typical and atypical Alzheimer disease. JAMA Neurol 74 (2017), 427–436.
122. Arendt, T., Stieler, J.T., Holzer, M., Tau and tauopathies. Brain Res Bull 126:Pt 3 (2016), 238–292.
123. Spillantini, M.G., Goedert, M., Tau protein pathology in neurodegenerative diseases. Trends Neurosci 21 (1998), 428–433.
124. Goedert, M., Spillantini, M.G., Jakes, R., et al. Multiple isoforms of human microtubule-associated protein tau: Sequences and localization in neurofibrillary tangles of Alzheimer's disease. Neuron 3 (1989), 519–526.
125. Sergeant, N., Delacourte, A., Buee, L., Tau protein as a differential biomarker of tauopathies. Biochim Biophys Acta 1739 (2005), 179–197.
126. Wang, Y., Mandelkow, E., Tau in physiology and pathology. Nat Rev Neurosci 17 (2016), 5–21.
127. Goedert, M., Jakes, R., Expression of separate isoforms of human tau protein: Correlation with the tau pattern in brain and effects on tubulin polymerization. EMBO J 9 (1990), 4225–4230.
128. Andreadis, A., Brown, W.M., Kosik, K.S., Structure and novel exons of the human tau gene. Biochemistry 31 (1992), 10626–10633.
129. Jovanov-Milosevic, N., Petrovic, D., Sedmak, G., et al. Human fetal tau protein isoform: Possibilities for Alzheimer's disease treatment. Int J Biochem Cell Biol 44 (2012), 1290–1294.
130. Fontaine, S.N., Sabbagh, J.J., Baker, J., et al. Cellular factors modulating the mechanism of tau protein aggregation. Cell Mol Life Sci 72 (2015), 1863–1879.
131. Lippens, G., Landrieu, I., Smet, C., et al. NMR meets tau: Insights into its function and pathology. Biomolecules, 6, 2016.
132. Simic, G., Babic Leko, M., Wray, S., et al. Tau protein hyperphosphorylation and aggregation in Alzheimer's disease and other tauopathies, and possible neuroprotective strategies. Biomolecules, 6, 2016, 6.
133. Bramblett, G.T., Goedert, M., Jakes, R., et al. Abnormal tau phosphorylation at Ser396 in Alzheimer's disease recapitulates development and contributes to reduced microtubule binding. Neuron 10 (1993), 1089–1099.
134. Goedert, M., Jakes, R., Crowther, R.A., et al. The abnormal phosphorylation of tau protein at Ser-202 in Alzheimer disease recapitulates phosphorylation during development. Proc Natl Acad Sci USA 90 (1993), 5066–5070.
135. Köpke, E., Tung, Y.C., Shaikh, S., et al. Microtubule-associated protein tau: Abnormal phosphorylation of a non-paired helical filament pool in Alzheimer disease. J Biol Chem 268 (1993), 24374–24384.
136. Kimura, T., Ishiguro, K., Hisanaga, S., Physiological and pathological phosphorylation of tau by Cdk5. Front Mol Neurosci, 7, 2014, 65.
137. Kuret, J., Chirita, C.N., Congdon, E.E., et al. Pathways of tau fibrillization. Biochim Biophys Acta 1739 (2005), 167–178.
138. Crowther, R.A., Straight and paired helical filaments in Alzheimer disease have a common structural unit. Proc Natl Acad Sci USA 88 (1991), 2288–2292.
139. Goedert, M., Jakes, R., Spillantini, M.G., et al. Tau protein in Alzheimer's disease. Biochem Soc Trans 23 (1995), 80–85.
140. Iqbal, K., Alonso Adel, C., Chen, S., et al. Tau pathology in Alzheimer disease and other tauopathies. Biochim Biophys Acta 1739 (2005), 198–210.
141. Goedert, M., Spillantini, M.G., Cairns, N.J., et al. Tau proteins of Alzheimer paired helical filaments: Abnormal phosphorylation of all six brain isoforms. Neuron 8 (1992), 159–168.
142. Delacourte, A., Sergeant, N., Wattez, A., et al. Vulnerable neuronal subsets in Alzheimer's and Pick's disease are distinguished by their tau isoform distribution and phosphorylation. Ann Neurol 43 (1998), 193–204.
143. Arai, T., Ikeda, K., Akiyama, H., et al. Distinct isoforms of tau aggregated in neurons and glial cells in brains of patients with Pick's disease, corticobasal degeneration and progressive supranuclear palsy. Acta Neuropathol 101 (2001), 167–173.
144. Umeda, Y., Taniguchi, S., Arima, K., et al. Alterations in human tau transcripts correlate with those of neurofilament in sporadic tauopathies. Neurosci Lett 359 (2004), 151–154.
145. Yoshida, M., Cellular tau pathology and immunohistochemical study of tau isoforms in sporadic tauopathies. Neuropathology 26 (2006), 457–470.
146. Chambers, C.B., Lee, J.M., Troncoso, J.C., et al. Overexpression of four-repeat tau mRNA isoforms in progressive supranuclear palsy but not in Alzheimer's disease. Ann Neurol 46 (1999), 325–332.
147. Perry, G., Mulvihill, P., Manetto, V., et al. Immunocytochemical properties of Alzheimer straight filaments. J Neurosci 7 (1987), 3736–3738.
148. Kovacs, G.G., Molecular pathological classification of neurodegenerative diseases: turning towards precision medicine. Int J Mol Sci, 17, 2016.
149. Ward, S.M., Himmelstein, D.S., Lancia, J.K., et al. Tau oligomers and tau toxicity in neurodegenerative disease. Biochem Soc Trans 40 (2012), 667–671.
150. Gerson, J.E., Castillo-Carranza, D.L., Kayed, R., Advances in therapeutics for neurodegenerative tauopathies: Moving toward the specific targeting of the most toxic tau species. ACS Chem Neurosci 5 (2014), 752–769.
151. Shafiei, S.S., Guerrero-Muñoz, M.J., Castillo-Carranza, D.L., Tau oligomers: cytotoxicity, propagation, and mitochondrial damage. Frontiers in Aging Neuroscience, 9, 2017.
152. Braak, H., Braak, E., Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol Aging 16 (1995), 271–278 discussion 278-84.
153. Liu, L., Drouet, V., Wu, J.W., et al. Trans-synaptic spread of tau pathology in vivo. PLoS ONE, 7, 2012, e31302.
154. Holmes, B.B., Diamond, M.I., Cellular mechanisms of protein aggregate propagation. Curr Opin Neurol 25 (2012), 721–726.
155. Pooler, A.M., Polydoro, M., Wegmann, S., et al. Propagation of tau pathology in Alzheimer's disease: Identification of novel therapeutic targets. Alzheimers Res Ther, 5, 2013, 49.
156. Crary, J.F., Trojanowski, J.Q., Schneider, J.A., et al. Primary age-related tauopathy (PART): A common pathology associated with human aging. Acta Neuropathol 128 (2014), 755–766.
157. Olney, N.T., Spina, S., Miller, B.L., Frontotemporal dementia. Neurol Clin 35 (2017), 339–374.
158. Mann, D.M.A., Snowden, J.S., Frontotemporal lobar degeneration: Pathogenesis, pathology and pathways to phenotype. Brain Pathol, 2017, 10.1111/bpa.12486.
159. Dickson, D.W., Kouri, N., Murray, M.E., et al. Neuropathology of frontotemporal lobar degeneration-tau (FTLD-tau). J Mol Neurosci 45 (2011), 384–389.
160. Hardy, J.A., Higgins, G.A., Alzheimer's disease: The amyloid cascade hypothesis. Science 256 (1992), 184–185.
161. Larner, A.J., Doran, M., Clinical phenotypic heterogeneity of Alzheimer's disease associated with mutations of the presenilin-1 gene. J Neurol 253 (2006), 139–158.
162. Campion, D., Dumanchin, C., Hannequin, D., et al. Early-onset autosomal dominant Alzheimer disease: Prevalence, genetic heterogeneity, and mutation spectrum. Am J Hum Genet 65 (1999), 664–670.
163. Finckh, U., Alberici, A., Antoniazzi, M., et al. Variable expression of familial Alzheimer disease associated with presenilin 2 mutation M239I. Neurology 54 (2000), 2006–2008.
164. Bird, T.D., Lampe, T.H., Nemens, E.J., et al. Familial Alzheimer's disease in American descendants of the Volga Germans: Probable genetic founder effect. Ann Neurol 23 (1988), 25–31.
165. Jack, C.R. Jr, Wiste, H.J., Lesnick, T.G., et al. Brain beta-amyloid load approaches a plateau. Neurology 80 (2013), 890–896.
166. Villemagne, V.L., Burnham, S., Bourgeat, P., et al. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: A prospective cohort study. Lancet Neurol 12 (2013), 357–367.
167. Jack, C.R. Jr, Wiste, H.J., Weigand, S.D., et al. Age-specific population frequencies of cerebral beta-amyloidosis and neurodegeneration among people with normal cognitive function aged 50-89 years: A cross-sectional study. Lancet Neurol 13 (2014), 997–1005.
168. Morris, J.C., Price, J.L., Pathologic correlates of nondemented aging, mild cognitive impairment, and early-stage Alzheimer's disease. J Mol Neurosci 17 (2001), 101–118.
169. Bennett, D.A., Schneider, J.A., Arvanitakis, Z., et al. Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology 66 (2006), 1837–1844.
170. Mufson, E.J., Malek-Ahmadi, M., Perez, S.E., et al. Braak staging, plaque pathology, and APOE status in elderly persons without cognitive impairment. Neurobiol Aging 37 (2016), 147–153.
171. Ghetti, B., Oblak, A.L., Boeve, B.F., et al. Invited review: Frontotemporal dementia caused by microtubule-associated protein tau gene (MAPT) mutations: A chameleon for neuropathology and neuroimaging. Neuropathol Appl Neurobiol 41 (2015), 24–46.
172. Ludolph, A.C., Kassubek, J., Landwehrmeyer, B.G., et al. Tauopathies with parkinsonism: Clinical spectrum, neuropathologic basis, biological markers, and treatment options. Eur J Neurol 16 (2009), 297–309.
173. Insel, P.S., Mattsson, N., Mackin, R.S., et al. Accelerating rates of cognitive decline and imaging markers associated with beta-amyloid pathology. Neurology 86 (2016), 1887–1896.
174. Jack, C.R. Jr, Therneau, T.M., Wiste, H.J., et al. Transition rates between amyloid and neurodegeneration biomarker states and to dementia: A population-based, longitudinal cohort study. Lancet Neurol 15 (2016), 56–64.
175. Jack, C.R. Jr, Holtzman, D.M., Biomarker modeling of Alzheimer's disease. Neuron 80 (2013), 1347–1358.
176. Tosun, D., Landau, S., Aisen, P.S., et al. Association between tau deposition and antecedent amyloid-beta accumulation rates in normal and early symptomatic individuals. Brain, 2017, 10.1093/brain/awx046.
177. Shimada, H., Kitamura, S., Shinotoh, H., et al. Association between Abeta and tau accumulations and their influence on clinical features in aging and Alzheimer's disease spectrum brains: A [11C]PBB3-PET study. Alzheimers Dement (Amst) 6 (2017), 11–20.
178. Jack, C.R. Jr, Wiste, H.J., Weigand, S.D., et al. Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity. Neurology 81 (2013), 1732–1740.
179. Crary, J.F., Primary age-related tauopathy and the amyloid cascade hypothesis: The exception that proves the rule?. J Neurol Neuromedicine 1 (2016), 53–57.
180. Conrad, C., Andreadis, A., Trojanowski, J.Q., et al. Genetic evidence for the involvement of tau in progressive supranuclear palsy. Ann Neurol 41 (1997), 277–281.
181. Di Maria, E., Tabaton, M., Vigo, T., et al. Corticobasal degeneration shares a common genetic background with progressive supranuclear palsy. Ann Neurol 47 (2000), 374–377.
182. Houlden, H., Baker, M., Morris, H.R., et al. Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype. Neurology 56 (2001), 1702–1706.
183. Xia, C.F., Arteaga, J., Chen, G., et al. [(18)F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease. Alzheimers Dement 9 (2013), 666–676.
184. Villemagne, V.L., Dore, V., Bourgeat, P., et al. Abeta-amyloid and tau imaging in dementia. Semin Nucl Med 47 (2017), 75–88.
185. Hall, B., Mak, E., Cervenka, S., et al. In vivo tau PET imaging in dementia: Pathophysiology, radiotracer quantification, and a systematic review of clinical findings. Ageing Res Rev 36 (2017), 50–63.
186. Agdeppa, E.D., Kepe, V., Liu, J., et al. 2-Dialkylamino-6-acylmalononitrile substituted naphthalenes (DDNP analogs): Novel diagnostic and therapeutic tools in Alzheimer's disease. Mol Imaging Biol 5 (2003), 404–417.
187. Smid, L.M., Kepe, V., Vinters, H.V., et al. Postmortem 3-D brain hemisphere cortical tau and amyloid-beta pathology mapping and quantification as a validation method of neuropathology imaging. J Alzheimers Dis 36 (2013), 261–274.
188. Okamura, N., Suemoto, T., Furumoto, S., et al. Quinoline and benzimidazole derivatives: Candidate probes for in vivo imaging of tau pathology in Alzheimer's disease. J Neurosci 25 (2005), 10857–10862.
189. Fodero-Tavoletti, M.T., Okamura, N., Furumoto, S., et al. 18F-THK523: A novel in vivo tau imaging ligand for Alzheimer's disease. Brain 134:Pt 4 (2011), 1089–1100.
190. Villemagne, V.L., Furumoto, S., Fodero-Tavoletti, M.T., et al. In vivo evaluation of a novel tau imaging tracer for Alzheimer's disease. Eur J Nucl Med Mol Imaging 41 (2014), 816–826.
191. Lemoine, L., Saint-Aubert, L., Marutle, A., et al. Visualization of regional tau deposits using (3)H-THK5117 in Alzheimer brain tissue. Acta Neuropathol Commun, 3, 2015, 40.
192. Okamura, N., Furumoto, S., Harada, R., et al. Novel 18F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease. J Nucl Med 54 (2013), 1420–1427.
193. Harada, R., Okamura, N., Furumoto, S., et al. [(18)F]THK-5117 PET for assessing neurofibrillary pathology in Alzheimer's disease. Eur J Nucl Med Mol Imaging 42 (2015), 1052–1061.
194. Okamura, N., Furumoto, S., Fodero-Tavoletti, M.T., et al. Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET. Brain 137:Pt 6 (2014), 1762–1771.
195. Tago, T., Furumoto, S., Okamura, N., et al. Structure-activity relationship of 2-Arylquinolines as PET imaging tracers for tau pathology in Alzheimer disease. J Nucl Med 57 (2016), 608–614.
196. Harada, R., Okamura, N., Furumoto, S., et al. 18F-THK5351: A novel PET radiotracer for imaging neurofibrillary pathology in Alzheimer disease. J Nucl Med 57 (2016), 208–214.
197. Ng, K.P., Pascoal, T.A., Mathotaarachchi, S., et al. Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain. Alzheimers Res Ther, 9, 2017, 25.
198. Fowler, J.S., Volkow, N.D., Wang, G.J., et al. Age-related increases in brain monoamine oxidase B in living healthy human subjects. Neurobiol Aging 18 (1997), 431–435.
199. Lowe, V.J., Curran, G., Fang, P., et al. An autoradiographic evaluation of AV-1451 Tau PET in dementia. Acta Neuropathol Commun, 4, 2016, 58.
200. Marquie, M., Normandin, M.D., Vanderburg, C.R., et al. Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann Neurol 78 (2015), 787–800.
201. Chien, D.T., Bahri, S., Szardenings, A.K., et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis 34 (2013), 457–468.
202. Johnson, K.A., Schultz, A., Betensky, R.A., et al. Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann Neurol 79 (2016), 110–119.
203. Schwarz, A.J., Yu, P., Miller, B.B., et al. Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages. Brain 139:Pt 5 (2016), 1539–1550.
204. Scholl, M., Lockhart, S.N., Schonhaut, D.R., et al. PET imaging of tau deposition in the aging human brain. Neuron 89 (2016), 971–982.
205. Cho, H., Choi, J.Y., Hwang, M.S., et al. In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum. Ann Neurol 80 (2016), 247–258.
206. Ossenkoppele, R., Schonhaut, D.R., Scholl, M., et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease. Brain 139:Pt 5 (2016), 1551–1567.
207. Ikonomovic, M.D., Abrahamson, E.E., Price, J.C., et al. [F-18]AV-1451 positron emission tomography retention in choroid plexus: More than “off-target” binding. Ann Neurol 80 (2016), 307–308.
208. Maruyama, M., Shimada, H., Suhara, T., et al. Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron 79 (2013), 1094–1108.
209. Hashimoto, H., Kawamura, K., Takei, M., et al. Identification of a major radiometabolite of [11C]PBB3. Nucl Med Biol 42 (2015), 905–910.
210. Hashimoto, H., Kawamura, K., Igarashi, N., et al. Radiosynthesis, photoisomerization, biodistribution, and metabolite analysis of 11C-PBB3 as a clinically useful PET probe for imaging of tau pathology. J Nucl Med 55 (2014), 1532–1538.
211. Marquie, M., Normandin, M.D., Meltzer, A.C., et al. Pathological correlations of [F-18]-AV-1451 imaging in non-alzheimer tauopathies. Ann Neurol 81 (2017), 117–128.
212. Sander, K., Lashley, T., Gami, P., et al. Characterization of tau positron emission tomography tracer [18F]AV-1451 binding to postmortem tissue in Alzheimer's disease, primary tauopathies, and other dementias. Alzheimers Dement 12 (2016), 1116–1124.
213. Spina, S., Schonhaut, D.R., Boeve, B.F., et al. Frontotemporal dementia with the V337M MAPT mutation: Tau-PET and pathology correlations. Neurology 88 (2017), 758–766.
214. Fodero-Tavoletti, M.T., Furumoto, S., Taylor, L., et al. Assessing THK523 selectivity for tau deposits in Alzheimer's disease and non-Alzheimer's disease tauopathies. Alzheimers Res Ther, 6, 2014, 11.
215. Ono, M., Sahara, N., Kumata, K., et al. Distinct binding of PET ligands PBB3 and AV-1451 to tau fibril strains in neurodegenerative tauopathies. Brain 140 (2017), 764–780.
216. Cho, H., Choi, J.Y., Hwang, M.S., et al. Subcortical 18 F-AV-1451 binding patterns in progressive supranuclear palsy. Mov Disord 32 (2017), 134–140.
217. Coakeley, S., Cho, S.S., Koshimori, Y., et al. Positron emission tomography imaging of tau pathology in progressive supranuclear palsy. J Cereb Blood Flow Metab, 2016 271678x16683695.
218. Smith, R., Schain, M., Nilsson, C., et al. Increased basal ganglia binding of 18 F-AV-1451 in patients with progressive supranuclear palsy. Mov Disord 32 (2017), 108–114.
219. Whitwell, J.L.V., Lowe, J., Tosakulwong, N., et al. [18 F]AV-1451 tau positron emission tomography in progressive supranuclear palsy. Mov Disord 32 (2017), 124–133.
220. Ishiki, A., Harada, R., Okamura, N., et al. Tau imaging with [18 F]THK-5351 in progressive supranuclear palsy. Eur J Neurol 24 (2017), 130–136.
221. Kikuchi, A., Okamura, N., Hasegawa, T., et al. In vivo visualization of tau deposits in corticobasal syndrome by 18F-THK5351 PET. Neurology 87 (2016), 2309–2316.
222. Passamonti, L., Vazquez Rodriguez, P., Hong, Y.T., et al. 18F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy. Brain 140 (2017), 781–791.
223. Kim, W.S., Kagedal, K., Halliday, G.M., Alpha-synuclein biology in Lewy body diseases. Alzheimers Res Ther, 6, 2014, 73.
224. Ueda, K., Fukushima, H., Masliah, E., et al. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc Natl Acad Sci USA 90 (1993), 11282–11286.
225. Marques, O., Outeiro, T.F., Alpha-synuclein: From secretion to dysfunction and death. Cell Death Dis, 3, 2012, e350.
226. Giasson, B.I., Murray, I.V., Trojanowski, J.Q., et al. A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly. J Biol Chem 276 (2001), 2380–2386.
227. Braak, H., Del Tredici, K., Rub, U., et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24 (2003), 197–211.
228. Spillantini, M.G., Crowther, R.A., Jakes, R., et al. alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci USA 95 (1998), 6469–6473.
229. Villar-Pique, A., Lopes da Fonseca, T., Outeiro, T.F., Structure, function and toxicity of alpha-synuclein: The Bermuda triangle in synucleinopathies. J Neurochem 139:suppl 1 (2016), 240–255.
230. Spires-Jones, T.L., Attems, J., Thal, D.R., Interactions of pathological proteins in neurodegenerative diseases. Acta Neuropathol, 2017, 10.1007/s00401-017-1709-7.
231. Spillantini, M.G., Parkinson's disease, dementia with Lewy bodies and multiple system atrophy are alpha-synucleinopathies. Parkinsonism Relat Disord 5 (1999), 157–162.
232. McKeith, I.G., Galasko, D., Kosaka, K., et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the consortium on DLB international workshop. Neurology 47 (1996), 1113–1124.
233. Uchikado, H., Lin, W.L., DeLucia, M.W., et al. Alzheimer disease with amygdala Lewy bodies: A distinct form of alpha-synucleinopathy. J Neuropathol Exp Neurol 65 (2006), 685–697.
234. Irwin, D.J., Grossman, M., Weintraub, D., et al. Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: A retrospective analysis. Lancet Neurol 16 (2017), 55–65.
235. Jellinger, K.A., Attems, J., Does striatal pathology distinguish Parkinson disease with dementia and dementia with Lewy bodies?. Acta Neuropathol 112 (2006), 253–260.
236. Ottolini, D., Cali, T., Szabo, I., et al. Alpha-synuclein at the intracellular and the extracellular side: Functional and dysfunctional implications. Biol Chem 398 (2017), 77–100.
237. Dehay, B., Bourdenx, M., Gorry, P., et al. Targeting alpha-synuclein for treatment of Parkinson's disease: Mechanistic and therapeutic considerations. Lancet Neurol 14 (2015), 855–866.
238. Dickson, D.W., Braak, H., Duda, J.E., et al. Neuropathological assessment of Parkinson's disease: Refining the diagnostic criteria. Lancet Neurol 8 (2009), 1150–1157.
239. Hawkes, C.H., Del Tredici, K., Braak, H., A timeline for Parkinson's disease. Parkinsonism Relat Disord 16 (2010), 79–84.
240. Lawand, N.B., Saade, N.E., El-Agnaf, O.M., et al. Targeting alpha-synuclein as a therapeutic strategy for Parkinson's disease. Expert Opin Ther Targets 19 (2015), 1351–1360.
241. Schenk, D.B., Koller, M., Ness, D.K., et al. First-in-human assessment of PRX002, an anti-alpha-synuclein monoclonal antibody, in healthy volunteers. Mov Disord 32 (2017), 211–218.
242. Eberling, J.L., Dave, K.D., Frasier, M.A., alpha-Synuclein imaging: A critical need for Parkinson's disease research. J Parkinsons Dis 3 (2013), 565–567.
243. Deramecourt, V., Bombois, S., Maurage, C.A., et al. Biochemical staging of synucleinopathy and amyloid deposition in dementia with Lewy bodies. J Neuropathol Exp Neurol 65 (2006), 278–288.
244. Barrett, P.J., Timothy Greenamyre, J., Post-translational modification of alpha-synuclein in Parkinson's disease. Brain Res 1628:Pt B (2015), 247–253.
245. Anderson, J.P., Walker, D.E., Goldstein, J.M., et al. Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J Biol Chem 281 (2006), 29739–29752.
246. Fodero-Tavoletti, M.T., Mulligan, R.S., Okamura, N., et al. In vitro characterisation of BF227 binding to alpha-synuclein/Lewy bodies. Eur J Pharmacol 617 (2009), 54–58.
247. Yu, L., Cui, J., Padakanti, P.K., et al. Synthesis and in vitro evaluation of alpha-synuclein ligands. Bioorg Med Chem 20 (2012), 4625–4634.
248. Bagchi, D.P., Yu, L., Perlmutter, J.S., et al. Binding of the radioligand SIL23 to alpha-synuclein fibrils in Parkinson disease brain tissue establishes feasibility and screening approaches for developing a Parkinson disease imaging agent. PLoS ONE, 8, 2013 e55031.
249. Zhang, X., Jin, H., Padakanti, P.K., et al. Radiosynthesis and in Vivo Evaluation of Two PET Radioligands for Imaging alpha-Synuclein. Appl Sci (Basel) 4 (2014), 66–78.
250. Chu, W., Zhou, D., Gaba, V., et al. Design, synthesis, and characterization of 3-(Benzylidene)indolin-2-one derivatives as ligands for alpha-synuclein fibrils. J Med Chem 58 (2015), 6002–6017.
251. Kudo, Y., Okamura, N., Furumoto, S., et al. 2-(2-[2-Dimethylaminothiazol-5-yl]ethenyl)-6- (2-[fluoro]ethoxy)benzoxazole: A novel PET agent for in vivo detection of dense amyloid plaques in Alzheimer's disease patients. J Nucl Med 48 (2007), 553–561.
252. Kikuchi, A., Takeda, A., Okamura, N., et al. In vivo visualization of alpha-synuclein deposition by carbon-11-labelled 2-[2-(2-dimethylaminothiazol-5-yl)ethenyl]-6-[2-(fluoro)ethoxy]benzoxazole positron emission tomography in multiple system atrophy. Brain 133:Pt 6 (2010), 1772–1778.
253. Mach, R.H., Chu, W., Zhou, D., et al. A PET radiotracer for imaging alpha synuclein aggregates in Parkinson's disease. J Labelled Comp Radiopharm, 58(suppl 1), 2015, S42.
254. Sundaram, G.S., Dhavale, D.D., Prior, J.L., et al. Fluselenamyl: A novel benzoselenazole derivative for PET detection of amyloid plaques (Abeta) in Alzheimer's disease. Sci Rep, 6, 2016, 35636.